MYC and neoplasm: Together, our findings reveal enhanced de novo serine biosynthesis driven by MYC as a novel metabolic adaptation in tumor development, with significant potential as a clinically relevant and actionable therapeutic vulnerability for MYC-driven MBGRP3.